Olema Stock Analysis

OLMA
 Stock
  

USD 2.48  0.14  5.34%   

The big decline in price over the last few months for Olema Pharmaceuticalsmay encourage investors to take a closer look at the company as it is trading at a share price of 2.48 on 121,066 in trading volume. The company executives failed to add value to investors and position the company supply of money to exploit market volatility in November. However, diversifying your holdings with Olema Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.69. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Olema Pharmaceuticals partners.
Please check Your Equity Center.
  
The Olema Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Olema Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Olema Stock analysis module also helps to analyze the Olema Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Olema Stock Analysis Notes

About 85.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Olema Pharmaceuticals recorded a loss per share of 1.99. The entity had not issued any dividends in recent years. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Olema Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about Olema Pharmaceuticals contact the company at 650 243 5555 or learn more at https://www.olema.com.

Olema Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Olema Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Olema Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Olema Pharmaceuticals generated a negative expected return over the last 90 days
Olema Pharmaceuticals has high historical volatility and very poor performance
Net Loss for the year was (71.1 M) with profit before overhead, payroll, taxes, and interest of 0.
Olema Pharmaceuticals currently holds about 240.71 M in cash with (50.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 85.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Catalyst watch Eyes on Lululemon, GameStop, Disney and Exxon Mobil - Seeking Alpha

Olema Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 100.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Olema Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Olema Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (0.2342) % which means that it has lost $0.2342 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.3866) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals management efficiency ratios could be used to measure how well olema pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Non Current Liabilities Total
2.4 M
Short Long Term Debt Total
5.2 M
Interest Expense
0.00
Total Operating Expenses
71.5 M
Beta
1.6353
Common Stock Total Equity
K

Technical Drivers

As of the 9th of December, Olema Pharmaceuticals holds the risk adjusted performance of (0.10), and Coefficient Of Variation of (1,377). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Olema Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have collected data for nineteen technical drivers for Olema Pharmaceuticals, which can be compared to its competitors. Please check Olema Pharmaceuticals standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if Olema Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 2.48 per share. Please also confirm Olema Pharmaceuticals total risk alpha, which is currently at (0.68) to check out the company can sustain itself at a future point.

Olema Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Olema Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Olema Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Olema Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Olema Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Olema Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Olema Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bohen Sean over two months ago via Macroaxis 
Purchase by Bohen Sean of 20000 shares of Olema Pharmaceuticals
Bohen Sean over two months ago via Macroaxis 
Acquisition by Bohen Sean of 20000 shares of Olema Pharmaceuticals subject to Rule 16b-3
Kovacs Shane William Charles over three months ago via Macroaxis 
Purchase by Kovacs Shane William Charles of 20000 shares of Olema Pharmaceuticals
Hrustanovic Gorjan over three months ago via Macroaxis 
Acquisition by Hrustanovic Gorjan of 21520 shares of Olema Pharmaceuticals subject to Rule 16b-3
Hrustanovic Gorjan over three months ago via Macroaxis 
Acquisition by Hrustanovic Gorjan of 21520 shares of Olema Pharmaceuticals subject to Rule 16b-3
Bvf Partners L P over three months ago via Macroaxis 
Olema Pharmaceuticals exotic insider transaction detected
Horn Kinney over six months ago via Macroaxis 
Exercise or conversion by Horn Kinney of 5253 shares of Olema Pharmaceuticals subject to Rule 16b-3
Horn Kinney over six months ago via Macroaxis 
Exercise or conversion by Horn Kinney of 5251 shares of Olema Pharmaceuticals subject to Rule 16b-3
Horn Kinney over six months ago via Macroaxis 
Exercise or conversion by Horn Kinney of 5251 shares of Olema Pharmaceuticals subject to Rule 16b-3
Myles David C over six months ago via Macroaxis 
Olema Pharmaceuticals exotic insider transaction detected
Bvf Partners L P over a year ago via Macroaxis 
Olema Pharmaceuticals exotic insider transaction detected
Harmon Cyrus over a year ago via Macroaxis 
Olema Pharmaceuticals exotic insider transaction detected

Olema Pharmaceuticals Technical and Predictive Indicators

Olema Pharmaceuticals Forecast Models

Olema Pharmaceuticals time-series forecasting models is one of many Olema Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Olema Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Olema Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Olema Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Olema shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Olema Pharmaceuticals. By using and applying Olema Stock analysis, traders can create a robust methodology for identifying Olema entry and exit points for their positions.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Olema Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Olema Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module
Please check Your Equity Center. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for analysis

When running Olema Pharmaceuticals price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Olema Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
100.3 M
Return On Assets
(0.23) 
Return On Equity
(0.39) 
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Olema Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.